60 completed, 10 terminated, 6 recruiting, 4 active not recruiting. 84 Phase 3, 8 Phase 2.
Follow Jazz Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stratification and Treatment in Early Psychosis Study - PROMOTE Cannabidiol (CBD), Placebo - Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis | Phase 3 | Not yet recruiting | University of Oxford | 586 | 2026-12-01 | 2026-10-08 |
| A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE CBD-OS, Placebo - Developmental and Epileptic Encephalopathy (DEE) | Phase 3 | Not yet recruiting | Jazz Pharmaceuticals | 120 | 2026-10-30 | 2026-07-24 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-11-02 |
| A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH Xywav, Placebo - Narcolepsy, Idiopathic Hypersomnia | Phase 3 | Recruiting | Jazz Pharmaceuticals | 120 | 2026-07-09 | 2026-10-08 |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Zanidatamab, Trastuzumab, Eribulin - Metastatic HER2-positive Breast Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 550 | 2024-08-13 | 2026-02-10 |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Zanidatamab, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 3 | Recruiting | Jazz Pharmaceuticals | 286 | 2024-07-19 | 2026-10-28 |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo - H3 K27M, Glioma | Phase 3 | Recruiting | Jazz Pharmaceuticals | 510 | 2023-01-23 | 2026-04-16 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures GWP42003-P, Placebo - Seizures Associated With EMAS | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2022-10-31 | 2025-02-03 |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 Everolimus, ONC201, Radiotherapy - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 433 | 2022-09-29 | 2026-10-21 |
| A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers Zanidatamab, Tislelizumab, Trastuzumab - Gastric Neoplasms, Gastroesophageal Adenocarcinoma | Phase 3 | Active not recruiting | Jazz Pharmaceuticals | 920 | 2021-12-02 | 2026-10-20 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer Atezolizumab, Lurbinectedin, Carboplatin - Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 660 | 2021-11-18 | 2026-09-09 |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity With Multiple Sclerosis | Phase 3 | Terminated | Jazz Pharmaceuticals | 56 | 2021-08-16 | 2024-12-11 |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures GWP42003-P - Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2021-05-19 | 2025-10-31 |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia Dociparstat, Control - Acute Myeloid Leukemia | Phase 3 | Terminated | Jazz Pharmaceuticals | 9 | 2021-04-30 | 2024-04-15 |
| Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder Nabiximols, Placebo - Post-Traumatic Stress Disorder | Phase 2 / Phase 3 | Withdrawn | Jazz Pharmaceuticals | 2021-02-01 | 2022-06-03 | |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity in Participants With Multiple Sclerosis | Phase 3 | Completed | Jazz Pharmaceuticals | 68 | 2020-12-21 | 2023-07-20 |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Nabiximols, Placebo - Multiple Sclerosis (MS) | Phase 3 | Terminated | Jazz Pharmaceuticals | 139 | 2020-10-01 | 2024-05-08 |
| Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure Dociparstat sodium, Placebo - Coronavirus Disease 2019 (COVID-19), Acute Lung Injury | Phase 2 / Phase 3 | Terminated | Jazz Pharmaceuticals | 27 | 2020-07-08 | 2022-08-30 |
| A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome GWP42003-P - Rett Syndrome, RTT | Phase 3 | Terminated | Jazz Pharmaceuticals | 21 | 2020-02-28 | 2022-08-08 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
Showing 20 of 84. Sign in to see all of them.
Pain (17) · Multiple Sclerosis (14) · Muscle Spasticity (9) · Narcolepsy (7) · Epilepsy (6) · Epilepsies, Myoclonic (4) · Fibromyalgia (4) · Hepatic Veno-Occlusive Disease (4) · Leukemia, Myeloid, Acute (4) · Peripheral Nervous System Diseases (4) · Seizures (4) · Anxiety Disorders (3) · Arthralgia (3) · Cancer Pain (3) · Lennox Gastaut Syndrome (3)
nabiximols (29) · Cannabidiol (13) · Sodium Oxybate (9) · brincidofovir (5) · defibrotide (4) · solriamfetol (4) · CPX-351 (3) · Cytarabine (3) · Sodium Chloride (3) · zanidatamab (3) · Capecitabine (2) · Cisplatin (2) · Daunorubicin (2) · Dronabinol (2) · Gemcitabine (2)
United States (49) · United Kingdom (43) · Spain (21) · France (19) · Germany (19) · Italy (17) · Poland (17) · Canada (15) · Netherlands (14) · Belgium (10) · Australia (9) · Czechia (9) · Israel (9) · Finland (8) · Romania (6)
Barbara Hoggart, MBBS, FRCA (2) · Jeremy R Johnson, MB ChB (2) · Murray Stein, MD (2) · Paul Richardson, M.D. (2) · Charles Craddock, Professor (1) · Christine B. Boers-Doets, MSc (1) · Christine Collin (1) · Christine Collin, MB BS MRCP FRCP (1) · Cris Constantinescu, MD PhD (1) · Elyad Davidson, M.D. (1) · Grace Wang, MD (1) · Hans Gelderblom, MD, PhD (1) · I. Jon Russell, PhD, MD (1)
PMID 25475413, PMID 15327042, PMID 33226332, PMID 33797076, PMID 33825230, PMID 34265088, PMID 34283019, PMID 34957550, PMID 37052803, PMID 37231094, PMID 40775196, PMID 12393437, PMID 15561385, PMID 16186518, PMID 16895262, PMID 17086911, PMID 17355549, PMID 17997224, PMID 19116896, PMID 19896326, PMID 20209489, PMID 20307378, PMID 20829244, PMID 21206549, PMID 21362108, PMID 21397402, PMID 21878454, PMID 22364685, PMID 22878432, PMID 23141881, PMID 24286114, PMID 24420962, PMID 26660428, PMID 26825712, PMID 27851688, PMID 29221779, PMID 29767845, PMID 29768152, PMID 30024784, PMID 30169321, PMID 30292744, PMID 30471270, PMID 30521757, PMID 30955420, PMID 31691827, PMID 31760835, PMID 31926465, PMID 32119035, PMID 32353246, PMID 32356515
2014 (5), 2023 (5), 2015 (4), 2019 (3), 2009 (2), 2018 (2), 2016 (1)